We are live on ! Find out more
BLRX icon

BioLineRX

28 hedge funds and large institutions have $1.47M invested in BioLineRX in 2024 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

137% more capital inflows, than outflows

Capital inflows: $489K | Capital outflows: $207K

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

0.26% more ownership

Funds ownership: 1.54% → 1.8% (+0.26%)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

3% less funds holding

Funds holding: 29 → 28 (-1)

85% less call options, than puts

Call options by funds: $33K | Put options by funds: $223K

Holders
28
Holders Change
-1
Holders Change %
-3.45%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
8
Reduced
6
Closed
5
Calls
$33​K
Puts
$223​K
Net Calls
-⁠$190​K
Net Calls Change
-⁠$422​K

BLRX Hedge Fund Activity: Q1 2024 in Review

28 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2024, worth a combined $1.47M — down 16% from $1.75M a quarter earlier.

Fund positioning in BLRX was balanced in Q1 2024: 5 funds opened new positions, 5 closed out, 8 added to existing stakes and 6 trimmed.

The largest buyer was Values First Advisors, adding an estimated $190K. The largest seller was Virtu Financial, exiting entirely with an estimated $48K sold.

  • 28 institutional investors held BioLineRX (BLRX) as of Q1 2024, down from 29 in Q4 2023.
  • Funds reported $1.47M of BioLineRX stock for Q1 2024, down 16% quarter-over-quarter.
  • 5 funds opened new BioLineRX positions in Q1 2024 and 5 closed out, a net change of 0 holders.
  • The largest BioLineRX buyer in Q1 2024 was Values First Advisors, an estimated $190K added.
  • The largest BioLineRX seller in Q1 2024 was Virtu Financial, an estimated $48K sold.

Based on aggregated 13F filings for Q1 2024.